Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Palayoor Website

Sanjeewani T. Palayoor, Ph.D.

Radiation Oncology Branch
Experimental Therapeutics Section
Special Volunteer
Center for Cancer Research
National Cancer Institute
Bldg 10/ Rm 3B49
9000 Rockville Pike
Bethesda, MD 20892
301 496 1401
301 480 1434


Dr. Palayoor received her education in India and worked at the Tata Memorial Hospital, Bombay before coming to the US. She did her postdoctoral research at the Yale Medical School, New Haven, CT and Dana Farber Cancer Institute, Boston, MA. She joined NIH in 1999.


Primary research objective is to identify and develop novel approaches to enhance the radiosensitivity of tumors.

- Nonsteroidal anti-inflammatory drugs (NSAIDs) as radiosensitizers.

- Cellular targets of NSAIDs pertinent in radiosensitization. COX-2 dependent and COX-2 independent targets.

- Gene expression analysis of tumor and normal cells treated with traditional NSAID ibuprofen, COX-2-specific inhibitors NS398 and celecoxib and COX-2 RNAi.

-NSAIDs have come under scrutiny because of the reports of cardiovascular toxicity associated with prolonged use of these drugs. Microarray analysis revealed that in coronary artery cells ibuprofen as well as celecoxib differentially expressed an array of genes associated with cardiovascular events.

- Hypoxia, Hypoxia-inducible factor (HIF) and radiosensitivity.

- HIF inhibitors as radiosensitizers.

- Gene expression analysis of prostate carcinoma cells treated with single and fractionated dose irradiation. Identify radiation-induced targets and to evaluate their potential for using radiation to prime cells for molecular targeted drug therapy.

-miRNA and mRNA expression in coronary artery cells following single and fractionated radiation.

This page was last updated on 7/31/2012.